Enveric Biosciences, a Naples─headquartered biotechnology company dedicated to the development of novel neuroplastogenic small─molecule...
Vous n'êtes pas connecté
CAMBRIDGE, Mass. — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents […]
Enveric Biosciences, a Naples─headquartered biotechnology company dedicated to the development of novel neuroplastogenic small─molecule...
An international team of scientists has found that poor organ health in the body can contribute to poor mental health. The study was published in the...
Psychiatric disorders often overlap, with shared symptoms making diagnosis challenging. Conditions like depression and anxiety, schizophrenia and...
Cyprus is rapidly running out of the antipsychotic drug Seroquel with the higher dosages especially being in short supply since early October, the...
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment...
NEEDHAM, Mass., Jan. 23, 2025 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage...
Insider Brief PRESS RELEASE — D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software,...
The CORONA virus pandemic also brought about a pandemic of mental illness. Approximately one billion people worldwide suffer from various psychiatric...
A brain implant using ultrasound shows promise for treating mood disorders like depression and anxiety with precision and minimal invasiveness.
Clifford Chance advised Keymed Biosciences on the deal. Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the...